C V Starr & Co. Inc. Makes New $1.59 Million Investment in Celularity Inc. (NASDAQ:CELU)

C V Starr & Co. Inc. purchased a new stake in Celularity Inc. (NASDAQ:CELU) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 764,069 shares of the company’s stock, valued at approximately $1,589,000. Celularity makes up 1.2% of C V Starr & Co. Inc.’s investment portfolio, making the stock its 6th largest holding. C V Starr & Co. Inc. owned about 3.21% of Celularity as of its most recent filing with the SEC.

Separately, Keynote Financial Services LLC lifted its position in shares of Celularity by 90.1% in the fourth quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock valued at $52,000 after acquiring an additional 11,863 shares in the last quarter. 19.02% of the stock is currently owned by hedge funds and other institutional investors.

Celularity Trading Down 2.4 %

Shares of NASDAQ CELU opened at $1.73 on Tuesday. Celularity Inc. has a 52 week low of $1.00 and a 52 week high of $5.69. The firm has a 50-day simple moving average of $1.83 and a 200-day simple moving average of $2.21.

Celularity Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.